When his $44 billion purchase of Twitter is finalized, Elon Musk will add social-media magnate to a resume that already includes electric vehicle entrepreneur, aerospace manufacturing innovator and world’s richest person. But in seeking to preserve what he deems to be free speech and make changes related to content moderation, Musk threatens to wipe out the brand-safety guardrails that have lured wary health and pharma brands onto the platform.
Source: MMM Online
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more
